

- 30 **Henningfield JE**, Moolchan ET, Zeller M. Regulatory strategies to reduce tobacco addiction in youth. *Tobacco Control* 2003;**12**(suppl 1):i14–24.
- 31 **Committee on Opportunities in Drug Abuse, Research Division of Neuroscience and Behavioral Health, Institute of Medicine.** *Pathways of addiction: opportunities in drug abuse research.* Washington DC: National Academy Press, 1996.
- 32 **Expert Panel, (Henningfield JE, Johanson CE Sellers EM, rapporteurs).** Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. *Drug Alcohol Dependence* 2003;**70**:S107–14.
- 33 **O'Brien CP.** Drug addiction and drug abuse. In: Hardman JG, Limbird LE, Molinoff PB, *et al.* eds. *Goodman & Gilman's the pharmacological basis of therapeutics.* New York: McGraw-Hill, 1996:557–77.
- 34 **Henningfield JE**, Kozlowski LT, Benowitz NL. A proposal to develop meaningful labeling for cigarettes. *JAMA* 1994;**272**:312–4.
- 35 **National Cancer Institute.** Risks associated with smoking cigarettes with low-machine measured yields of tar and nicotine. *Smoking and Tobacco Control Monograph No. 13.* Bethesda, Maryland: US Department of Health and Human Services, National Institutes of Health, National Cancer Institutes, 2002. (NIH Publication No. 02–5074.)
- 36 **Ingebrethsen BJ.** Deposition provided in litigation brought on behalf of "The People of the State of California, *et al.* versus Philip Morris, Inc. *et al.* " March 24 and 25, 1998.
- 37 **Holmes JC**, Seligman RB, and Philip Morris, Inc. Idea No. 99—Means of controlling particle size of cigarette smoke and of incorporating volatile flavors. American Legacy Foundation Tobacco Documents website. Bates No. 2021627703, 2021627706. 1957.
- 38 **Douglas CE.** Taking aim at the bull's eye: the nicotine in tobacco products. *Tobacco Control* 1998;**7**:215–8.
- 39 **Kessler D.** *A question of intent: a great American battle with a deadly industry.* New York, NY: Public Affairs, 2001.
- 40 **Henningfield JE**, Fant RV, Gitchell J, *et al.* Tobacco dependence. Global public health potential for new medications development and indications. *Ann NY Acad Sci* 2000;**909**:247–56.
- 41 **Balster RL**, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. *Drug and Alcohol Dependence* 2003;**70**:S13–40.
- 42 **Slade J**, Henningfield JE. Tobacco product regulation: context and issues. *Food and Drug Law Journal* 1998;**53**:43–74.
- 43 **Houtsmuller EJ**, Fant RV, Eissenberg TE, *et al.* Flavor improvement does not increase abuse liability of nicotine chewing gum. *Pharmacology, Biochemistry and Behavior* 2002;**72**:559–68.
- 44 **Warner KE**, Slade J, Sweanor DT. The emerging market for long-term nicotine maintenance. *JAMA* 1997;**278**:1087–92.
- 45 **Henningfield JE**, Slade J. Tobacco dependence medications: public health and regulatory issues. *Food and Drug Law Journal* 1998;**53**:75–114.
- 46 **Schuh KJ**, Schuh LM, Henningfield JE, *et al.* Nicotine nasal spray and vapor inhaler: abuse liability assessment. *Psychopharmacology (Berl)* 1997;**130**:352–61.

The lighter side



© King Features Syndicate. Reprinted with permission of Torstar Syndication Services.